Bristol-Myers Squibb (BMY) Ownership
Score
Ownership data loads after the page opens.
Ownership data loads after the page opens.
BMY price $63.43 +1.11 +1.78%
Stocklytics score rationale: value 64, quality 72, growth 47.
AI Score 75. Bristol-Myers Squibb has a strong market cap of $127.71 billion and a solid net profit margin of approximately 18.5%, indicating good profitability. However, its high price-to-earnings ratio of about 13.82 and a price-to-book ratio of 5.45 suggest that it may be overvalued relative to its earnings and assets, which could limit upside potential
Bristol-Myers Squibb Company operates in Healthcare, within the Drug Manufacturers - General industry. Its overall score is 59.
The shares have a P/E of 13.8 and a price-to-book ratio of 5.5. The value score is 64.
The quality score is 67, supported by a net margin of 18.5%. The dividend yield is 4.0%.
The growth score is 46, indicating growth is the weakest of the reported factor scores.
Growth is a relative concern given the growth score of 46. The price-to-book ratio of 5.5 may also be relevant when assessing valuation.
Insights · Dividends · Forecast · Financials · Learn